In public health evaluation, it is common to translate program outcomes into cost-effectiveness metrics. The goal is not to place a value on human life, but rather to illustrate how relatively modest investments in prevention can generate substantial, life-saving impact.

Consider a naloxone distribution program.

Imagine a program distributes 10,000 naloxone kits in a year. To make the math simple, assume each kit costs $50. That means the direct supply cost is:

Most behavioral health programs are doing meaningful work. They are serving individuals in crisis, coordinating care, building coalitions, and responding to evolving federal and state requirements. The commitment is real, and the impact on communities is significant.

Yet many program leaders quietly feel vulnerable as grant terms approach their end. Not because the work is weak, but because sustaining it often requires securing new funding. When a federal award sunsets, the question becomes whether the program can compete effectively for the next opportunity, whether from the same agency or a different source altogether.